Cartesian Therapeutics

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$387
$5,840
$5,840
$8,266
Gross Profit
5,657
5,657
7,994
EBITDA
-56,641
-12,865
-196,386
EBIT
-56,824
-13,048
-196,658
Net Income
-24,183
-56,824
-56,824
-177,658
Net Change In Cash
387
5,840
5,840
8,266
Free Cash Flow
7,492
-16,519
-16,519
-23,350
Cash
219,198
103,418
103,418
76,911
Basic Shares
23,896
5,414
5,414
5,160

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$26,004
$110,777
$85,077
$16,597
Gross Profit
24,451
108,740
85,077
16,597
EBITDA
-235,064
39,838
-5,158
-65,593
EBIT
-235,907
37,801
-6,877
-67,320
Net Income
-219,710
35,379
-25,687
-68,876
Net Change In Cash
26,004
110,777
85,077
16,597
Cost of Revenue
-7,418
-24,628
48,513
Free Cash Flow
-51,367
-32,832
-61,467
34,066
Cash
76,911
106,438
114,057
138,685
Basic Shares
5,170
4,862
3,810
3,373

Earnings Calls

Quarter EPS
2024-09-30
-$1.13
2024-06-30
$0.54
2024-03-31
-$10.50
2023-12-31
-$0.07